INC completes new CEO succession plan, promotes new execs

INC Research ($INCR) has seen through its plan of transitioning its chief exec of three years, Jamie Macdonald, from the top seat as the CRO also promotes two new execs to its leadership team. 

INC announced back in July that J. Macdonald would be stepping down and replaced by a new Macdonald, Alistair, who this week becomes its new chief. He will give up his former COO role, which will now be taken over by Dr. Michael Gibertini, who had served as the company’s president of clinical development.

As part of the shifts at the top, Tara Fitzgerald, EVP of biometrics, has become the new president of clinical development services. 


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

J. Macdonald will stay on in a transitional role to help out the new CEO until the end of February next year, the CRO said in a statement.

"Michael and Tara both bring experienced leadership, extensive industry and in-depth organizational knowledge and a strategic vision to help guide the future growth and success of INC Research," said A. Macdonald.

“As president, clinical development, Michael has continued to grow and build on INC’s therapeutic expertise as a key differentiator while enhancing our scientific focus to deliver truly innovative clinical development solutions for customers.

“Tara is a proven leader who has delivered exceptional results during her tenure with INC, guiding our biometrics business to deliver consistently strong performance while also providing senior-level leadership for numerous other business-critical initiatives. We look forward to her continued leadership in further optimizing our overall delivery while driving growth across our key value chains.”

He added that he was “thrilled” to take on the CEO role “at this exciting time in our growth.”

INC, which has a market cap of $2.49 billion, was marginally up this morning on the news by 0.1%. 

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

The Mayo Clinic tapped data analytics firm nference to build out an AI-powered engine to collate its years of clinical records and pathology work.

At the annual J.P. Morgan Healthcare Conference, major CRO Charles River Laboratories and Takeda announced a new preclinical tie-up.